Ellie Merrill

Ellie Merrill asked what would constitute meaningful Phase 2 data for Syfovre in combination with APL-3007 next year, and sought clarification on the 50% penetration comment for Empaveli in C3G and IC-MPGN, specifically if it represents a base case or a challenging treatment threshold.

Answer

Co-founder, CEO, and President Dr. Cedric Francois explained that the GALE study with APL-3007, a subcutaneous siRNA, aims to lower systemic C3 by 90%, providing a stoichiometric advantage to Syfovre in the eye. He expects this to enable every-three-month dosing instead of every two, and to significantly increase efficacy. Regarding Empaveli, Dr. Francois clarified that 'up to 50% of the epidemiology' could be treated, noting a conservative epidemiology estimate and a very strong launch with over 5% penetration in Q4.

Ellie Merrill asked about expectations for the Phase 2 data of Syfovre in combination with APL-3007, what would constitute meaningful results, and sought clarification on the 50% penetration comment for Empaveli in C3G/IC-MPGN, specifically if it's a base case or if half the population will be challenging to treat.

Answer

Co-Founder, CEO, and President Cedric Francois explained that APL-3007, a subcutaneous siRNA, aims to lower systemic C3 by approximately 90%, providing a stoichiometric advantage to Syfovre in the eye. He anticipates that successful data could enable every three-month dosing instead of every two, significantly increasing efficacy. Regarding Empaveli, Francois clarified that 'up to 50% of the epidemiology' could be treated, noting that Apellis's conservative epidemiology estimate, combined with a strong launch (over 5% penetration in Q4), supports confidence in this target.